Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study
K.J. Mason, Oras Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Juliet N. Barker, Zenas Z N Yiu, Catherine Smith, C.E.M. Griffiths, the BADBIR Study Group, Jonathan Barker, Simon Morrison, Anthony Bewley, Ian Evans, C.E.M. Griffiths, Shehnaz Ahmed, Brian Kirby, Elise Kleyn, Philip Laws, Philip Hampton, Oras Alabas, Kathleen McElhone, Zenas Z N Yiu, Teena Mackenzie, Tess McPherson, Ruth Murphy, Anthony D. Ormerod, Shernaz Walton, Nick J. Reynolds, Catherine Smith, Alexa R. Shipman, Christina Ye, Olivia Hughes, Richard B. Warren, Fiona Browne, Ian Evans, Brian Kirby, Linda Lawson, Philip Laws, Teena Mackenzie, Tess McPherson, Ruth Murphy, Caroline Owen, Eleanor Pearson, Josh Richards, Catherine Smith, Richard B. Warren
Abstract
It is unknown why some patients with psoriasis experience long-term effectiveness with their first biologic monotherapy. Our aim was to compare the baseline demographic, disease, genotypic, clinical and lifestyle characteristics of patients with psoriasis registered in the British Association of Dermatologists Biologics and Immunomodulators Register and the aligned Biomarkers and Stratification to Optimise outcomes in Psoriasis study who were designated as ‘super responders’ (SRs), defined as patients on their first biologic with more than 5 years continuous biologic monotherapy, or ‘super nonresponders’ (SNRs), defined as patients on their first biologic who had discontinued at least two biologics in their first year of treatment, to biologic therapy. Female sex, shorter study follow-up, higher Dermatology Life Quality Index, high frequency of adalimumab, less frequency of ustekinumab at registration, and higher number of comorbidities were associated with SNRs compared with SRs.